Compugen (NASDAQ:CGEN) Stock Crosses Above 200-Day Moving Average of $0.00

Compugen Ltd. (NASDAQ:CGEN) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as high as $3.16. Compugen shares last traded at $3.03, with a volume of 12,781 shares changing hands.

Separately, Zacks Investment Research downgraded Compugen from a “buy” rating to a “hold” rating in a research note on Monday, July 29th.

The business’s 50 day moving average is $3.56. The company has a quick ratio of 5.11, a current ratio of 5.11 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $163.10 million, a PE ratio of -7.34 and a beta of 2.66.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings data on Monday, May 20th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.03. On average, equities research analysts predict that Compugen Ltd. will post -0.54 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC increased its position in Compugen by 3.2% during the 2nd quarter. ARK Investment Management LLC now owns 8,496,641 shares of the biotechnology company’s stock worth $32,627,000 after purchasing an additional 267,086 shares during the period. Nikko Asset Management Americas Inc. increased its position in Compugen by 84.0% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,631,037 shares of the biotechnology company’s stock worth $6,263,000 after purchasing an additional 744,447 shares during the period. Taylor Frigon Capital Management LLC increased its position in Compugen by 11.5% during the 2nd quarter. Taylor Frigon Capital Management LLC now owns 760,424 shares of the biotechnology company’s stock worth $2,920,000 after purchasing an additional 78,278 shares during the period. Defender Capital LLC. increased its position in Compugen by 7.2% during the 1st quarter. Defender Capital LLC. now owns 311,333 shares of the biotechnology company’s stock worth $1,299,000 after purchasing an additional 20,800 shares during the period. Finally, Stockman Wealth Management Inc. acquired a new position in Compugen during the 1st quarter worth approximately $286,000. Institutional investors own 29.43% of the company’s stock.

About Compugen (NASDAQ:CGEN)

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

Read More: Dividend Achievers

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.